Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 20;43(9):1157-1167.
doi: 10.1200/JCO.24.01154. Epub 2024 Oct 4.

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group

Affiliations

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group

Michael R Sargen et al. J Clin Oncol. .

Abstract

Purpose: The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients.

Methods: A Children's Oncology Group-led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise.

Results: Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications.

Recommendations: (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Ira Dunkel has relationships with AstraZeneca (consultant), Bristol-Myers Squibb/Celgene (consultant and Memorial Sloan Kettering Cancer Center receives research funding from this company), IO Biotech (consultant), GlaxoSmithKline (consultant), and Novartis (consultant and Memorial Sloan Kettering Cancer Center receives research funding from this company). Elena B. Hawryluk has relationships with Apogee (advisory board member), Skin Analytics (consultant work ended 1/10/2023), DermTech (research collaboration, investigator initiated study), Gritstone Bio, Inc (spouse owns stock and is employed by company), PathAI (spouse serves on advisory board), and Predictive Oncology, Inc (spouse owns stock and serves on board of directors). Theodore W. Laetsch has relationships with Advanced Microbubbles (owns stock), Novartis (consultant), Bayer (consultant), Aptitude Health (consultant), Jumo Health (consultant), Massive Bio (consultant), Medscape (consultant), AI Therapeutics (consultant), Jazz Pharmaceuticals (consultant), GentiBio (consultant), Menarini (consultant), Pyramid Biosciences (consultant), Targeted Oncology (consultant), Treeline Biosciences (consultant), ITM Oncologics (consultant), Lilly (research funding), Roche/Genentech (research funding), Taiho Oncology (research funding), Advanced Accelerator Applications/Novartis (research funding), Bristol-Myers Squibb (research funding), BioAtla (research funding), Hoffmann-LaRoche (research funding), Pfizer (research funding), Bayer (research funding), Turning Point Therapeutics (research funding). Victor G. Prieto has relationships with Merck (consultant), Castle (consultant), and Orlucent (consultant).

References

    1. Paulson KG, Gupta D, Kim TS, et al.: Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol 156:57–64, 2020 - PMC - PubMed
    1. Siegel RL, Giaquinto AN, Jemal A: Cancer statistics, 2024. CA Cancer J Clin 74:12–49, 2024 - PubMed
    1. Geller AC, Clapp RW, Sober AJ, et al.: Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. J Clin Oncol 31:4172–8, 2013 - PMC - PubMed
    1. Sreeraman Kumar R, Messina JL, Reed D, et al.: Pediatric Melanoma and Atypical Melanocytic Neoplasms. Cancer Treat Res 167:331–69, 2016 - PubMed
    1. Quan VL, Zhang B, Zhang Y, et al.: Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms. J Invest Dermatol 140:1599–1608, 2020 - PubMed

LinkOut - more resources